UnitedHealth (UNH) Reports Q3 Earnings: What Key Metrics Have to Say

UnitedHealth Group (UNH) reported $113.16 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 12.2%. EPS of $2.92 for the same period compares to $7.15 a year ago.The reported revenue represents a surprise of -0.17% over the Zacks Consensus Estimate of $113.36 billion. With the consensus EPS estimate being $2.75, the EPS surprise was +6.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how UnitedHealth performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Operating Statistics - Medical Care Ratio: 89.9% versus the seven-analyst average estimate of 90.9%.UnitedHealthcare Customer Profile - People Served - Commercial - Domestic - Risk-based: 8.44 million versus the five-analyst average estimate of 8.45 million.UnitedHealthcare Customer Profile - People Served - Commercial - Domestic - Fee-based: 21.49 million compared to the 21.56 million average estimate based on five analysts.UnitedHealthcare Customer Profile - People Served - Total Community and Senior: 20.2 million compared to the 20.33 million average estimate based on five analysts.Revenues- Investment and other income: $1.13 billion versus the eight-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of -31.1%.Revenues- Products: $13.3 billion compared to the $13.8 billion average estimate based on eight analysts. The reported number represents a change of +5.3% year over year.Revenues- Services: $9.75 billion versus the eight-analyst average estimate of $9.31 billion. The reported number represents a year-over-year change of +7.1%.Revenues- Premiums: $88.98 billion versus the eight-analyst average estimate of $89.18 billion. The reported number represents a year-over-year change of +14.9%.Revenues- Optum Insight: $4.92 billion versus the six-analyst average estimate of $4.96 billion. The reported number represents a year-over-year change of -0.3%.Revenues- Optum Rx: $39.68 billion versus $38.58 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +16% change.Revenues- Optum Health: $25.9 billion versus the six-analyst average estimate of $25.42 billion. The reported number represents a year-over-year change of -0.1%.Revenues- UnitedHealthcare- Total: $87.07 billion versus the six-analyst average estimate of $87.02 billion. The reported number represents a year-over-year change of +16.3%.View all Key Company Metrics for UnitedHealth here>>>Shares of UnitedHealth have returned +6% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks